Trial Profile
Phase I trial of NKTR-105 in patients with refractory solid tumours.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Jun 2010
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Nektar Therapeutics
- 20 May 2010 According to a Nektar Therapeutics media release, interim results will be presented as a poster at ASCO 2010.
- 08 Mar 2009 New trial record.
- 17 Feb 2009 The first patients have been dosed according to a Nektar Therapeutics media release.